Cogan-Reese Syndrome

Cogan-Reese syndrome is a very rare eye disease. It affects the clear front window of the eye (the cornea), the colored part (the iris), and the fluid-drainage angle of the eye. It belongs to a group of diseases called iridocorneal endothelial (ICE) syndromes. In Cogan-Reese syndrome, the inner cell layer of the cornea grows in an abnormal way, spreads over the iris and the drainage angle, and causes many changes in the eye.

Cogan-Reese syndrome (also called iris nevus / Cogan-Reese variant of iridocorneal endothelial (ICE) syndrome) is an extremely rare eye disease that usually affects only one eye. In this condition, the inner surface of the cornea (the clear front window of the eye) is lined by abnormal endothelial cells. These cells slowly grow across the drainage angle of the eye and over the iris (the colored part). This can cause pigmented, often pedunculated (on a small stalk) nodules or flat pigmented patches on the iris, distortion of the iris shape, and formation of peripheral anterior synechiae (areas where the iris sticks to the cornea). Over time, this process often leads to secondary angle-closure glaucoma and corneal edema (swelling), which can seriously threaten vision if untreated.

Cogan-Reese syndrome is one of three ICE variants; the others are progressive essential iris atrophy and Chandler syndrome. In Cogan-Reese, iris nodules and pigmented lesions are more prominent, while severe iris atrophy is less common compared with the other subtypes. The disease is usually unilateral, typically occurs in young-to-middle-aged adults, and is more common in women. The cause is not fully understood, but the abnormal corneal endothelium may behave like an epithelial-like membrane, contracting and pulling on the iris and angle. Some studies have detected herpes simplex virus DNA in the anterior chamber of ICE eyes, suggesting a possible viral trigger in some patients.

Because the abnormal cells are progressive and can scar the drainage angle, glaucoma from Cogan-Reese syndrome is often difficult to control and may not respond well to medicines alone. Many people eventually require glaucoma surgery and sometimes corneal transplantation if the cornea becomes permanently cloudy. Early diagnosis, careful pressure control, and long-term follow-up with a glaucoma or cornea specialist are therefore essential to protect vision.

This disease almost always starts in only one eye, not both. It is slowly progressive. Over time, the abnormal cell layer can lead to swelling of the cornea, dark spots or nodules on the iris, and high eye pressure (glaucoma). If glaucoma is not controlled, it can damage the optic nerve and reduce vision.

Cogan-Reese syndrome is usually seen in young to middle-aged adults. It seems to be more common in women and in people with light skin, but it can appear in many groups. It is not usually found in several family members, so doctors think it is not a typical inherited disease.

Other names

Doctors use several other names for Cogan-Reese syndrome. It is often called iris nevus (Cogan-Reese) syndrome or iris naevus (Cogan-Reese) syndrome. “Nevus” means a spot or mole made of pigment cells, so this name describes the dark spots that grow on the iris.

Some authors call it the iris nevus subtype of ICE syndrome or the Cogan-Reese variant of iridocorneal endothelial syndrome. These names remind us that this is one special form inside the larger ICE syndrome group.

Types and patterns

Doctors usually see Cogan-Reese syndrome as one main disease. But they describe different patterns or “types” of how it looks in the eye. These types help explain what they see with the microscope light (slit lamp), not separate diseases.

1. Nodular iris nevus type – In this pattern, there are raised, small, dark brown or black bumps on the iris surface. They may look like tiny moles on stalks (pedunculated nodules). These nodules are one of the most typical signs of Cogan-Reese syndrome.

2. Flat or “matted” pigment type – In some patients, instead of clear bumps, the iris surface looks smudged, rough, or coated with flat brown pigment. This matted look can spread over a large part of the iris and may hide the normal iris pattern.

3. Early-stage pattern – In early disease, the cornea may still look clear. There may be only a few small nodules or mild changes in the pupil shape. The drainage angle may already start to close because abnormal cells grow over it, but the eye pressure can still be normal.

4. Advanced-stage pattern – In advanced disease, the cornea can become swollen and cloudy, the iris can look very distorted, and the pupil can be pulled to one side or become irregular. Many parts of the iris can stick to the cornea (peripheral anterior synechiae), and high eye pressure with glaucoma is common.

Within the larger ICE syndrome family there are three classic clinical subtypes: progressive essential iris atrophy, Chandler syndrome, and Cogan-Reese (iris nevus) syndrome. Cogan-Reese is the form where iris nodules and pigmented changes are most obvious.

Causes and risk factors

Doctors do not know the exact single cause of Cogan-Reese syndrome. It seems to be an acquired problem of the corneal inner cell layer, not a birth defect and not a usual genetic disease. Many possible factors may play a role together.

1. Abnormal corneal endothelial cells – The basic problem in ICE syndromes is that corneal endothelial cells change their behavior. They start to act more like skin cells, multiply, and migrate onto the iris and angle. This abnormal cell behavior is thought to be the main driver of Cogan-Reese syndrome.

2. Migration of cells to the angle and iris – These changed endothelial cells move from the cornea to the iridocorneal angle and iris surface. As they move, they form a thin membrane that contracts and pulls on the iris and angle structures, causing distortion and closure.

3. Formation of abnormal basement membrane – The migrating cells can lay down an abnormal basement membrane (support layer). This thick and irregular layer can further disturb the normal fluid flow and help the iris stick to the cornea.

4. Peripheral anterior synechiae (PAS) – When the iris sticks to the cornea in the angle, it forms PAS. These adhesions block the drainage channels and are an important cause of high eye pressure and glaucoma in Cogan-Reese syndrome.

5. Secondary angle-closure glaucoma – The blocked angle leads to secondary angle-closure glaucoma. Glaucoma itself is not the first cause, but it is a key result of the abnormal membrane and synechiae and becomes a major factor in ongoing damage.

6. Corneal endothelial pump failure – When too many abnormal cells cover the corneal inner surface, the normal pump function that keeps the cornea clear can fail. This leads to corneal swelling and further damage, which worsens vision and disease severity.

7. Possible viral infection (herpes simplex virus) – Some studies have found evidence of herpes simplex virus in patients with ICE syndrome. This has led to the idea that a past viral infection could trigger the cell changes in the cornea.

8. Possible viral infection (Epstein–Barr virus) – Epstein–Barr virus has also been suggested as a possible trigger in some ICE cases. The virus might infect corneal cells, change their DNA activity, and cause them to behave in an abnormal way.

9. Non-hereditary cell mutation – Even without a clear virus, a random mutation in a small group of corneal endothelial cells could start the disease. Because most cases are one-sided and do not run in families, this kind of local mutation is a likely explanation.

10. Female sex as a risk factor – ICE syndromes, including Cogan-Reese syndrome, are reported more often in women. This suggests that female sex may be a risk factor, although it is not a direct cause.

11. Young to middle adult age – Many patients are diagnosed between the third and fifth decade of life. This age pattern suggests that some adult-life factor, such as hormones or viral exposure, may be involved.

12. Unilateral disease pattern – The fact that almost always only one eye is affected supports the idea of a local trigger in that eye, such as a localized infection or micro-injury to the corneal endothelium.

13. Chronic low-grade inflammation – Long-standing irritation or mild inflammation in the front of the eye may encourage abnormal healing and overgrowth of endothelial-like cells, although strong proof is still limited.

14. Immune-mediated responses – Some experts think that the immune system might react to altered endothelial cells and contribute to tissue damage and membrane formation, but this idea still needs more research.

15. Angle anatomy and structural susceptibility – Natural small differences in the shape of the drainage angle or iris may make some eyes more likely to develop angle closure when an abnormal membrane grows.

16. Previous eye surgery or trauma (possible trigger) – In a few reports, ICE-like changes appeared after eye surgery or trauma. This suggests that mechanical injury might sometimes trigger corneal endothelial changes, but this is not common.

17. Pigmented iris nevus formation – In Cogan-Reese syndrome, pigment cells in the iris form nodules and plaques. The interaction between these pigment cells and the abnormal membrane may help nodules grow and change the iris appearance.

18. Long-standing high eye pressure – Once glaucoma develops, high pressure can further damage the cornea and iris. This makes the disease picture worse and is an important factor in later stages of the condition.

19. Genetic background (general eye structure) – While no strong inherited pattern is seen, a person’s general genetic makeup may influence corneal cell behavior or angle shape, making ICE changes more or less likely.

20. Unknown or idiopathic factors – In many patients, no clear trigger is found. For this reason, doctors still describe the cause of Cogan-Reese syndrome as largely idiopathic (unknown), with several theories but no single proven explanation.

Symptoms and signs

The symptoms of Cogan-Reese syndrome can be mild at first and then slowly get worse. Symptoms often come from corneal swelling and from glaucoma caused by angle closure.

1. Blurred vision in one eye – Many people first notice that vision in one eye is not clear. The world may look misty, especially in the morning or in bright light. This can be due to corneal swelling or high eye pressure.

2. Slow loss of sharpness (reduced visual acuity) – Over time, the ability to see small letters on an eye chart can slowly decline in the affected eye. This may come from long-term corneal changes or optic nerve damage from glaucoma.

3. Eye pain or aching – Some patients feel a dull ache or sharp pain in the affected eye, especially when eye pressure is high or when corneal swelling is severe. This pain can also spread as headache around the eye.

4. Headache on the affected side – Glaucoma attacks or sustained high eye pressure can cause headache, often on the same side as the diseased eye. The pain may get worse in dark rooms or when the pupil is larger.

5. Redness of the eye – The white of the eye can look red because high pressure and irritation cause tiny blood vessels to dilate. Redness may come and go or stay for longer periods during flare-ups.

6. Sensitivity to light (photophobia) – People may feel discomfort or pain in bright light. Corneal swelling and iris changes can make the eye more sensitive to light than usual.

7. Seeing halos or colored rings around lights – When the cornea is swollen, light scatters as it enters the eye. This can cause rainbow-like rings or halos around lamps, car headlights, or the sun.

8. Glare and difficulty driving at night – Because light does not focus properly, glare can be strong, especially at night. This makes driving or walking in low light more difficult and tiring.

9. Change in iris color (heterochromia) – The affected iris may look darker or lighter than the iris of the normal eye. Pigment spots or nodules can also change the color pattern, so the two eyes do not match.

10. Visible dark spots or nodules on the iris – Tiny raised or flat dark lesions can be seen on the surface of the iris. These spots may increase over time and are a key sign of Cogan-Reese syndrome.

11. Distorted pupil shape (corectopia) – The pupil may be pulled off center, become oval, or have an irregular shape. This happens when the abnormal membrane contracts and tugs on parts of the iris.

12. Very small or fixed pupil – In some patients, the pupil becomes abnormally small or reacts poorly to light. This can add to vision problems and cause more trouble in dim light.

13. Cloudy or hazy cornea – The cornea may look gray or steamy because fluid builds up inside it. This cloudiness can change during the day and makes vision hazy.

14. Feeling of pressure or fullness in the eye – High eye pressure can create a sense that the eye is “full” or being pushed from inside. This feeling may come with pain or just discomfort.

15. No symptoms in very early disease – In some people, early Cogan-Reese syndrome is found by chance during an eye exam. They may not notice any change in vision until the disease is more advanced.

Diagnostic tests

Doctors use a mix of physical exams, manual tests, lab and pathological tests, electrodiagnostic tests, and imaging tests to diagnose Cogan-Reese syndrome. These tests help confirm the ICE pattern, show how far the disease has progressed, and rule out other conditions such as iris melanoma.

Physical exam tests

1. Detailed medical and eye history – The doctor asks when symptoms started, which eye is affected, and whether there is pain, halos, or vision loss. They also ask about past eye infections, trauma, surgery, and family eye disease. This history helps suggest ICE syndrome because it usually involves one eye, slow change, and no strong family pattern.

2. Visual acuity test (eye-chart test) – The patient reads letters or symbols on a chart at distance and near. This is a simple way to measure how much the disease has affected central vision and to follow changes over time.

3. External eye inspection – The doctor looks at the eyes without special tools. They compare the color of both irises, look for redness, swelling, and differences in pupil size or shape. One eye that looks different, with color change and pupil distortion, raises suspicion for Cogan-Reese syndrome.

4. Pupillary light reflex and shape check – Using a small light, the doctor tests how the pupils react and notes their shape and position. Poor reaction, an off-center pupil (corectopia), or small fixed pupil are common in ICE syndromes, especially with significant iris membrane contraction.

Manual clinical tests

5. Slit-lamp biomicroscopy of cornea and iris – The slit lamp is a special microscope with a bright, narrow light. The doctor uses it to see corneal swelling, abnormal endothelium pattern, iris nodules, pigment plaques, and any tiny holes or thinning in the iris. This is a key test to recognize Cogan-Reese syndrome.

6. Intraocular pressure measurement (tonometry) – A tonometer measures eye pressure. High pressure suggests glaucoma. In Cogan-Reese syndrome, glaucoma is common and may be hard to control, so regular pressure checks are essential.

7. Gonioscopy (angle examination) – The doctor uses a small mirrored lens on the eye to look at the drainage angle between cornea and iris. They can see if parts of the iris are stuck to the cornea (peripheral anterior synechiae) and how much of the angle is closed. These findings support an ICE-related angle-closure process.

8. Corneal pachymetry (corneal thickness test) – A simple probe or imaging device measures corneal thickness. Corneas in ICE syndrome can be thicker because of edema. Knowing the true thickness helps interpret eye-pressure readings and plan surgery if needed.

9. Visual field (perimetry) testing – The patient looks into a dome and presses a button when they see small lights. This test maps side vision. Loss of visual field is a sign of glaucoma damage, so perimetry helps assess how much harm high pressure has caused.

Lab and pathological tests

10. Histopathology of corneal tissue (after transplant) – In advanced cases needing corneal transplantation, the removed corneal button can be studied under a microscope. Pathologists see abnormal endothelial-like cells and membranes typical of ICE syndromes, confirming the diagnosis.

11. Iris or angle biopsy (to rule out melanoma) – Very rarely, if the iris nodules look suspicious for cancer, a small biopsy may be taken. Lab study can show that the lesion is related to ICE (with benign nevus tissue and abnormal membrane) rather than malignant melanoma.

12. Blood tests for viral antibodies – Some doctors may order blood tests for herpes simplex virus or Epstein–Barr virus antibodies. Positive results do not prove cause, but they support the theory that past viral infection might have triggered the corneal cell changes.

13. General blood tests to rule out other diseases – Tests for autoimmune markers or systemic inflammation can help exclude other causes of iris changes, corneal edema, or glaucoma. A normal result supports the idea that the problem is local ICE syndrome, not a body-wide disease.

Electrodiagnostic tests

14. Visual evoked potentials (VEP) – Small electrodes on the head measure brain responses to visual patterns. VEP can show how well signals travel from the eye to the brain. This test may be used in difficult cases to separate loss from corneal opacity and glaucoma from other nerve diseases.

15. Pattern electroretinogram (pattern ERG) – This test measures electrical responses from the retina, especially ganglion cells that are affected by glaucoma. A reduced signal can support the presence of functional damage from high eye pressure in Cogan-Reese syndrome.

16. Full-field electroretinogram (ERG) – A broader ERG checks global retina function. It is usually normal in ICE syndromes but can be helpful to rule out retinal diseases that also cause vision loss, ensuring that the main problem is cornea and glaucoma, not the retina.

Imaging tests

17. Specular microscopy of the corneal endothelium – This machine takes detailed pictures of the inner corneal cell layer. In Cogan-Reese syndrome, the cells look abnormal, with dark and bright areas and irregular shapes. Specular microscopy helps confirm the ICE pattern and follow changes over time.

18. Anterior segment optical coherence tomography (AS-OCT) – AS-OCT uses light waves to create cross-section images of the front of the eye. It shows corneal thickness, angle closure, and iris position. It can help visualize membranes and synechiae that are hard to see with a slit lamp alone.

19. Ultrasound biomicroscopy (UBM) – UBM uses high-frequency ultrasound to see structures in and behind the iris and angle. It is very useful when the cornea is cloudy, because it can still show peripheral anterior synechiae, iris cysts, and angle closure in Cogan-Reese syndrome.

20. Optic nerve and retinal imaging (OCT or fundus photography) – Imaging of the optic nerve head and retina helps detect and monitor glaucoma damage. Thinning of the nerve fiber layer on OCT or changes in the optic disc on photos confirm the impact of long-term high pressure in the affected eye.

Non-Pharmacological (Non-Drug) Treatments and Therapies

These measures do not cure Cogan-Reese syndrome, because the underlying endothelial abnormality is structural and chronic, but they help protect the eye, reduce symptoms, and support overall management.

1. Regular specialist eye follow-up
   Seeing a glaucoma or cornea specialist at the intervals they recommend is one of the most important “treatments.” The doctor checks intraocular pressure (IOP), optic nerve health, and corneal clarity with slit-lamp examination and imaging. Early detection of pressure spikes or worsening synechiae allows timely adjustment of medicines or surgery, reducing the risk of permanent optic nerve damage and vision loss.

2. Strict adherence to prescribed eye drops
   Although eye drops are drugs, following the prescribed schedule is a non-pharmacological behavior that dramatically influences outcomes. Taking drops exactly as instructed helps keep eye pressure stable and reduces fluctuations that can worsen glaucoma damage. Using reminder alarms, medication charts, or family support can improve adherence and make long-term treatment easier to maintain.

3. Correct eye-drop instillation technique
   Proper drop technique (washing hands, not touching the bottle tip to the eye, placing one drop in the lower fornix, and gently closing the eye without squeezing) ensures the right dose reaches the eye and lowers contamination risk. Punctal occlusion (gently pressing the inner corner of the eyelids) for 1–2 minutes can reduce systemic absorption and side effects while increasing local effect of glaucoma drops.

4. Protective eyewear and trauma avoidance
   Because the affected eye already has compromised structures, avoiding extra trauma is important. Using protective glasses during sports, manual work, or high-risk activities lowers the chance of blunt injury that might trigger decompensation of the cornea or sudden pressure rises. Simple safety habits can prevent serious complications in an eye that is already vulnerable.

5. Control of systemic blood pressure and vascular risk factors
   Healthy blood pressure and good control of diabetes, cholesterol, and smoking status help the optic nerve and retinal circulation. Although Cogan-Reese syndrome is primarily an anterior segment disease, glaucoma damage is influenced by overall blood flow to the optic nerve. Working with a primary-care doctor on cardiovascular health supports the eye’s ability to handle chronically elevated or fluctuating IOP.

6. Avoidance of unnecessary topical or systemic steroids
   Steroids can be helpful in episodes of inflammation, but long-term or unsupervised steroid use can raise IOP and speed up glaucoma damage. Patients with Cogan-Reese syndrome should avoid over-the-counter steroid eye drops or prolonged systemic steroids without specialist advice. If steroids are essential for another condition, the eye doctor may monitor pressures more closely and adjust glaucoma treatment.

7. Limiting contact lens wear when cornea is compromised
   If the cornea is edematous or endothelial function is poor, contact lenses (especially poorly fitted or extended-wear lenses) can worsen hypoxia and swelling. In many patients with advanced ICE syndromes, glasses are safer than contact lenses. When contact lenses are needed (for example, a scleral lens for irregular cornea), they should be fitted and monitored by a cornea specialist.

8. Hyperosmotic saline drops or ointment use (behavioural aspect)
   Hypertonic saline (if prescribed) is used as a supportive measure to temporarily reduce corneal edema. The non-pharmacological part is using it correctly in relation to daily activities—for example using it before important visual tasks to improve clarity. Understanding that it offers temporary symptom relief but does not treat the root cause helps set realistic expectations.

9. Low-vision rehabilitation if vision is significantly impaired
   If advanced glaucoma or corneal damage has reduced visual acuity or visual field, referral to low-vision services can greatly improve quality of life. Training might include using magnifiers, high-contrast reading tools, large-print devices, and orientation-and-mobility techniques. These interventions do not fix the eye but help the person function better in daily life and maintain independence.

10. Workplace and school adaptations
    Adjusting lighting, glare control, font size, screen contrast, and reading distance in school or work environments can reduce visual strain and help compensate for reduced contrast sensitivity or field loss. Simple adjustments (larger monitors, higher resolution, adjustable brightness, frequent breaks) support comfort and productivity and are an important part of holistic care.

11. Sleep and head positioning strategies
    Some glaucoma patients benefit from avoiding sleeping with the eye pressed into the pillow or with the head positioned far below heart level for long periods, which might transiently increase IOP. Using a slightly elevated pillow and avoiding pressure on the affected eye may help reduce nocturnal pressure spikes, although this is supportive rather than a primary treatment.

12. Avoiding excessive caffeine and fluid “boluses”
    Large, rapid fluid intake and heavy caffeine consumption may transiently raise IOP in some individuals with glaucoma. Moderating intake—especially avoiding sudden drinking of very large volumes at once—may help smooth pressure fluctuations. This does not replace glaucoma therapy but is a reasonable lifestyle adjustment often advised in glaucoma clinics.

13. Smoking cessation and avoidance of second-hand smoke
    Smoking contributes to vascular damage and oxidative stress in the eye. Although not specific to Cogan-Reese syndrome, quitting smoking improves overall ocular and systemic health and may support better optic nerve resilience. Smoking cessation programs, counselling, and nicotine-replacement strategies can be part of a comprehensive treatment plan.

14. UV and glare protection with appropriate sunglasses
    Sunglasses that block UVA and UVB and reduce glare can increase visual comfort, particularly if the cornea is slightly edematous or if irregularities cause light scatter. Reduced glare can make daily activities such as driving (where allowed), walking outdoors, or reading more comfortable and may reduce photophobia or tearing.

15. Psychological support and counselling
    Living with a rare, chronic eye disease and the risk of progressive vision loss can cause anxiety, low mood, or fear about the future. Access to counselling, peer-support groups, or mental-health services can help patients cope, adhere to treatment, and make informed decisions about surgery. Emotional well-being is an important but often overlooked part of eye-care.

16. Education about disease and warning signs
    Clear explanations about what Cogan-Reese syndrome is, why glaucoma develops, and which warning signs (sudden pain, halos, rapid vision drop) need urgent care empower patients. Better understanding of the condition increases treatment adherence and ensures people seek help quickly during pressure crises or sudden corneal decompensation.

17. Careful planning of pregnancy and hormonal changes
    In patients of child-bearing age, pregnancy can influence fluid balance and medication choices. Pre-pregnancy counselling with the eye doctor and obstetrician helps plan safe glaucoma control, possible surgery timing, and medication adjustments. This anticipatory planning reduces risks to both mother and baby while maintaining stable eye pressure.

18. Screening and support for the fellow eye
    Although ICE syndromes are typically unilateral, the fellow eye should still be examined regularly. Having one eye at higher risk makes preservation of the better eye critical. Protective strategies (avoiding trauma, addressing other ocular risk factors like myopia or diabetes) help keep the fellow eye as healthy as possible.

19. Careful coordination with other medical procedures
    When other surgeries (like orthopedic or dental procedures) are planned, informing the surgical team about the eye condition is important. Proper positioning, avoiding excessive venous congestion, and planning peri-operative medications with the ophthalmologist can reduce risks of IOP spikes or corneal injury during general anesthesia or prolonged positioning.

20. Healthy overall lifestyle (exercise, diet, stress control)
    Regular moderate exercise, a balanced diet, and stress-management strategies (such as relaxation exercises or mindfulness) support cardiovascular and brain health. While they do not reverse Cogan-Reese syndrome, they help maintain optic nerve perfusion and overall resilience to chronic disease. A healthier body can better tolerate long-term medical therapy and surgical recovery.

---

Drug Treatments

Important: These medicines are used to treat secondary glaucoma, inflammation, or corneal edema, not the structural cause itself. Exact drug choice, dose, and schedule must always be decided by an eye specialist. The drugs below are FDA-approved for glaucoma or ocular conditions in general; they are used off-label or on-label as appropriate for patients with ICE-related glaucoma.

1. Timolol (topical beta-blocker)
   Timolol eye drops reduce aqueous humor production, lowering IOP. A common adult dose is 1 drop of 0.25–0.5% solution in the affected eye once or twice daily. It is usually taken in the morning (and sometimes evening). Timolol’s purpose is to prevent optic-nerve damage by lowering pressure. Mechanistically, it blocks beta-adrenergic receptors in the ciliary body. Possible side effects include burning, dry eye, slowed heart rate, low blood pressure, bronchospasm in asthma, and fatigue.

2. Betaxolol (selective beta-blocker)
   Betaxolol is similar to timolol but more selective for beta-1 receptors, which may make it slightly safer for some patients with mild airway disease. Typical adult dosing is 1 drop twice daily. It reduces aqueous production to lower IOP. Side effects can include ocular irritation, mild blurred vision, bradycardia, and, less commonly, breathing difficulty. It may be chosen when a beta-blocker is needed but the doctor wants a more cardio-selective profile.

3. Brimonidine (alpha-2 adrenergic agonist)
   Brimonidine lowers IOP by both reducing aqueous production and increasing uveoscleral outflow. It is commonly dosed as 1 drop three times daily, though schedules vary. Its purpose is to enhance pressure control, often combined with other agents. Mechanistically, it stimulates alpha-2 receptors. Side effects may include allergic conjunctivitis, redness, dry mouth, fatigue, and, rarely, low blood pressure or drowsiness, so caution is used in children.

4. Dorzolamide (topical carbonic anhydrase inhibitor)
   Dorzolamide inhibits carbonic anhydrase in the ciliary body, reducing bicarbonate formation and aqueous production. It is often used as 1 drop three times daily, or twice daily in combination products. It helps lower IOP when beta-blockers alone are not enough. Side effects may include stinging, bitter taste, corneal edema, or allergy. Systemic acidosis is rare with topical therapy but is considered if multiple carbonic anhydrase inhibitors are used.

5. Brinzolamide (topical carbonic anhydrase inhibitor)
   Brinzolamide works similarly to dorzolamide but has a slightly different formulation that some patients find more comfortable. Typical dosing is 1 drop two or three times daily. It helps further reduce IOP by decreasing aqueous production. Side effects may include blurred vision immediately after instillation, ocular discomfort, and rare allergic reactions. Combination with other glaucoma drops is common.

6. Latanoprost (prostaglandin analog)
   Latanoprost increases uveoscleral outflow, often providing powerful once-nightly IOP reduction. Typical adult dosing is 1 drop at bedtime. It is frequently used as first-line therapy in open-angle glaucoma and is also used in complex secondary glaucomas when the angle is still at least partially open. Side effects include conjunctival hyperemia, eyelash growth, iris darkening, mild periocular skin pigmentation, and rare macular edema, especially in eyes with other risk factors.

7. Travoprost (prostaglandin analog)
   Travoprost has a mechanism similar to latanoprost and is also dosed once daily in the evening. It aims to enhance outflow and keep pressures low over 24 hours. Side effects are comparable: redness, eyelash growth, iris color change, and possible periocular pigmentation changes. It may be chosen if response to other prostaglandin analogs is inadequate or if a preservative-free version is desired.

8. Bimatoprost (prostaglandin analog)
   Bimatoprost is another potent prostaglandin analog that increases aqueous outflow. Common dosing is 1 drop once daily at night. It is often used when strong IOP lowering is needed. Similar cosmetic side effects (lash growth, iris darkening) occur, and some patients have more redness or irritation. In susceptible individuals, there is a small risk of cystoid macular edema, so retina status is monitored in complex eyes.

9. Netarsudil (Rho-kinase inhibitor, often in combo with latanoprost)
   Netarsudil increases trabecular outflow and lowers episcleral venous pressure. It may be used alone once daily or combined with latanoprost for enhanced effect. Its purpose is to further lower IOP when other classes are insufficient. Side effects include conjunctival hyperemia, corneal verticillata (benign whorl-like corneal changes), and mild discomfort. In complex anterior-segment disease, corneal findings are monitored carefully.

10. Acetazolamide (oral carbonic anhydrase inhibitor)
    Acetazolamide tablets are systemic agents used short-term or intermittently in more severe pressure elevations. Typical adult doses might be 250–500 mg two to four times daily, adjusted to kidney function and tolerance. It strongly reduces aqueous production, helping control IOP crises while surgery is arranged. Side effects include tingling in fingers/toes, fatigue, metallic taste, kidney stone risk, metabolic acidosis, and rare severe reactions, so close medical supervision is essential.

11. Mannitol (intravenous hyperosmotic agent)
    Mannitol is used in acute, severe IOP spikes when vision is in immediate danger. It is given as an IV infusion in hospital at doses such as 1–2 g/kg under careful monitoring. It works by drawing fluid out of the eye and brain via osmotic gradient. Side effects can include fluid overload, electrolyte disturbances, kidney stress, and heart failure in vulnerable patients, so it is reserved for emergencies.

12. Topical hyperosmotic agents (e.g., sodium chloride 5% drops/ointment)
    Hypertonic saline solutions and ointments draw excess water out of the cornea, temporarily reducing edema and improving clarity. Typical dosing may be four times daily for drops and at bedtime for ointment, as directed. They do not lower IOP directly but improve symptoms like blurred vision and glare due to swelling. Common side effects include transient stinging and mild surface irritation.

13. Prednisolone acetate (topical corticosteroid)
    Prednisolone acetate 1% is a strong steroid used to calm anterior-segment inflammation when present. It is usually started at several times per day and then tapered. Its purpose is to reduce inflammatory cells and proteins that worsen pain or photophobia. Side effects include steroid-induced IOP rise, increased cataract risk, delayed wound healing, and higher infection risk, so glaucoma patients are monitored closely during use.

14. Loteprednol (softer topical corticosteroid)
    Loteprednol is a “soft” steroid designed to have lower risk of raising IOP, though monitoring is still required. It is often dosed several times daily, then tapered. It helps control milder inflammation or post-surgical irritation. Side effects include burning, temporary blurred vision, and potential steroid response in sensitive individuals. It can be useful when some steroid effect is needed but risk of pressure response is a concern.

15. Topical non-steroidal anti-inflammatory drugs (NSAIDs)
    NSAID eye drops (for example, ketorolac formulations) can help manage post-operative pain or reduce the risk of cystoid macular edema after intraocular surgery. They are usually dosed one to four times daily, depending on product and indication. Side effects include stinging, delayed corneal healing if overused, and rare corneal melts in compromised corneas, so they are used with caution in ICE-affected eyes.

16. Cycloplegic agents (e.g., atropine, cyclopentolate)
    Cycloplegics temporarily paralyze the ciliary muscle and dilate the pupil. In Cogan-Reese eyes, they may be used to relieve ciliary spasm-related pain or stabilize the anterior segment after surgery. Dosing varies from once daily to several times per day. Side effects include light sensitivity, blurred near vision, and, in susceptible patients, risk of angle closure, so their use is carefully individualized.

17. Combination glaucoma drops (e.g., timolol–dorzolamide, timolol–brimonidine)
    Fixed-combination drops provide two mechanisms in one bottle, improving adherence and limiting preservative exposure. Typical dosing is one drop twice daily. They reduce aqueous production and may enhance outflow, giving stronger pressure lowering than either agent alone. Side effects combine those of the components, so cardiovascular, respiratory, and allergy risks are considered.

18. Topical lubricants and gel tears
    Preservative-free artificial tears and gels relieve irritation and dryness that can be caused by multiple glaucoma drops and corneal surface changes. Dosing can range from a few times per day to hourly, as needed. They do not affect IOP but improve comfort and allow better tolerance of essential medicines. Side effects are minimal, mainly short-lived blurring after thicker gels.

19. Antiviral agents (e.g., oral acyclovir) when herpetic disease is suspected
    If a clinician suspects a herpes-related trigger or concurrent herpetic keratitis, oral antivirals may be used at doses such as 400–800 mg several times daily for a defined course, then sometimes lower-dose prophylaxis. They work by inhibiting viral DNA replication. Side effects can include nausea, headache, and kidney strain at high doses, so hydration and renal function are monitored.

20. Post-surgical anti-fibrotic agents (e.g., mitomycin-C used intra-operatively)
    In glaucoma filtration surgery, mitomycin-C may be applied to reduce scarring and keep the drainage bleb functioning. It is not a daily patient medicine but an intra-operative adjunct. It acts by inhibiting fibroblast proliferation. Potential complications include thin avascular blebs, higher risk of late infection, and wound-healing problems, so dosing and exposure time are carefully controlled by the surgeon.

---

Dietary Molecular Supplements

These supplements do not treat Cogan-Reese syndrome directly but may support general eye and vascular health. Always discuss any supplement with a doctor, especially if other conditions or medicines are present.

1. Omega-3 fatty acids (fish oil or algae-based)
   Omega-3 fatty acids (EPA/DHA) may support retinal blood flow and reduce ocular surface inflammation. Typical dietary supplement doses range from 500–1000 mg combined EPA/DHA daily, taken with meals to improve absorption. Functionally, omega-3s are precursors to anti-inflammatory mediators and help stabilize tear film. They may reduce dry-eye symptoms in patients using multiple glaucoma drops and support general cardiovascular health.

2. Vitamin C
   Vitamin C is a water-soluble antioxidant that helps protect ocular tissues from oxidative stress. A common supplemental dose is 250–500 mg daily, often from diet plus a multivitamin. It participates in collagen synthesis and scavenges free radicals produced by light exposure and metabolism. Maintaining adequate vitamin C through fruits, vegetables, or supplements can support corneal and scleral health, although it does not reverse ICE changes.

3. Vitamin E
   Vitamin E is a fat-soluble antioxidant located in cell membranes, where it protects lipids from peroxidation. Typical supplemental amounts might be 100–200 IU daily, under medical guidance, especially if combined with other fat-soluble vitamins. It supports general retinal and vascular health. Because high doses may increase bleeding risk or interact with anticoagulant medicines, dosing should be discussed with healthcare providers.

4. Lutein and zeaxanthin
   Lutein and zeaxanthin are carotenoids concentrated in the macula, where they filter blue light and act as antioxidants. Supplemental doses often fall between 6–20 mg of lutein plus smaller amounts of zeaxanthin daily. They help support macular health and visual function in bright light. While not specific to Cogan-Reese syndrome, protecting the macula is valuable in eyes already at risk from glaucoma or surgical interventions.

5. Vitamin D
   Vitamin D has widespread roles in immune modulation and bone health. Doses vary depending on baseline levels but commonly range from 800–2000 IU daily under supervision. Adequate vitamin D status may support immune balance and overall wellness, which indirectly benefits chronic disease management. Levels can be measured by blood test, and dosing adjusted to avoid deficiency or excessive levels.

6. Coenzyme Q10 (CoQ10)
   CoQ10 is involved in mitochondrial energy production and acts as an antioxidant. Typical supplement doses range from 100–200 mg daily with a meal containing fat. Experimental data suggest CoQ10 may support retinal and optic-nerve cell resilience to stress, though strong evidence in ICE syndromes is lacking. It may be considered as part of a general neuro-protective strategy after discussion with a doctor.

7. Magnesium
   Magnesium participates in hundreds of enzymatic reactions and helps regulate vascular tone and nerve function. Supplemental doses often range from 200–400 mg of elemental magnesium daily. Some glaucoma research explores magnesium’s potential role in improving blood flow to the optic nerve, though evidence remains limited. Excess magnesium can cause diarrhea or interact with kidney disease, so personalized advice is important.

8. Curcumin (from turmeric)
   Curcumin has anti-inflammatory and antioxidant properties. Standardized curcumin supplements are often taken at doses of 500–1000 mg per day of curcuminoids, sometimes with piperine to enhance absorption. It may modestly reduce systemic inflammation and oxidative stress, potentially supporting vascular health. Because curcumin can interact with anticoagulants and affect gallbladder conditions, medical guidance is essential.

9. Resveratrol
   Resveratrol, found in grapes and berries, is a polyphenol with antioxidant and vascular effects. Typical supplement doses range from 100–250 mg daily. In lab studies, resveratrol can influence cell survival pathways and reduce oxidative stress, but clinical evidence in eye disease is still evolving. It should be used cautiously in people on blood thinners or with liver issues.

10. Probiotic formulations
    Probiotics provide beneficial gut bacteria that may support immune balance and reduce systemic inflammation. Doses are usually given as colony-forming units (for example, 1–10 billion CFU daily), depending on the product. A healthier gut–immune axis could potentially influence chronic inflammatory states that coexist with eye disease, though this is indirect. People with severe immune compromise should discuss probiotics carefully with their physicians.

---

Emerging / Regenerative and Immune-Modulating Drug Concepts

Currently, no stem-cell or regenerative drug is specifically approved to treat Cogan-Reese syndrome or ICE syndromes. The items below describe broad research directions and immune-supportive concepts, not standard care. Participation in clinical trials is the safest way to access such therapies.

1. Cultured corneal endothelial cell therapy
   Researchers are exploring injection or transplantation of lab-grown corneal endothelial cells to restore pump function in corneal diseases. In theory, replacing the abnormal ICE endothelium with healthy cells might improve corneal clarity. These approaches are still experimental and are not routine for Cogan-Reese syndrome. Dosing, safety, and long-term outcomes are being evaluated in controlled trials and must not be attempted outside research settings.

2. Rho-kinase inhibitor–assisted endothelial regeneration
   Rho-kinase inhibitors, beyond lowering IOP, may help corneal endothelial cells migrate and heal in some conditions. Investigators are studying whether these drugs could support endothelial recovery after surgery or in dystrophies. Their use as a “regenerative” approach in ICE remains theoretical, and any dosing is currently off-label and individualized by specialists. More research is needed before routine use in Cogan-Reese eyes.

3. Mesenchymal stem-cell–derived factors
   Some experimental studies use mesenchymal stem cells or their secreted factors to modulate inflammation and fibrosis in various organs. In eye research, these cells are being explored for corneal healing and optic-nerve protection. Such therapies are not approved for ICE syndromes, and dosing protocols are experimental. Safety concerns include unwanted immune reactions, inappropriate tissue growth, and infection risk.

4. Immune-modulating biologic agents (systemic)
   Biologic drugs that target specific immune pathways are used in autoimmune eye diseases. In theory, carefully chosen biologics might dampen abnormal immune responses related to viral or inflammatory triggers of endothelial change. However, no biologic is currently licensed specifically for Cogan-Reese syndrome, and systemic immunosuppression carries significant risks. Any such treatment would be highly individualized and reserved for complex cases in specialized centers.

5. Neuro-protective agents for the optic nerve
   Research into neuro-protective drugs (including brimonidine’s potential neuro-protective effect, citicoline, and others) aims to help optic-nerve cells survive despite elevated IOP. Dosing depends on the agent and is still being tested in clinical studies. While these drugs may eventually complement pressure-lowering therapy, they are currently adjuncts rather than replacements for established glaucoma management.

6. Gene-therapy concepts
   Gene therapy has shown promise in some inherited retinal diseases. For ICE syndromes, where the exact cause is not clearly genetic, gene therapy is not yet applicable. Nonetheless, as understanding of the molecular pathways behind abnormal endothelial behavior grows, future gene-targeted strategies may be explored. At present, there are no approved gene-therapy products for Cogan-Reese syndrome.

---

Surgical Treatments

Because glaucoma secondary to Cogan-Reese syndrome is often resistant to medicines, surgery is frequently required to protect vision.

1. Trabeculectomy (filtering surgery)
   Trabeculectomy creates a new drainage pathway under the conjunctiva, allowing aqueous humor to leave the eye through a small flap in the sclera and form a filtering “bleb.” Mitomycin-C is often used to reduce scarring. It is done when IOP remains too high despite maximal medical therapy. The goal is long-term IOP reduction and preservation of the optic nerve, though failure from scarring or membrane growth is possible.

2. Glaucoma drainage implants (tube shunts)
   Tube devices (such as Ahmed or Baerveldt implants) are placed when trabeculectomy is unlikely to succeed or has failed. A small tube is inserted into the anterior chamber and connected to a plate under the conjunctiva, where fluid is absorbed. This procedure is common in ICE-related glaucoma, which tends to scar aggressively. It aims to provide stable, long-term pressure control in complex eyes.

3. Goniosynechialysis combined with cataract or glaucoma surgery
   In some cases with relatively recent peripheral anterior synechiae, surgeons may mechanically separate the iris from the trabecular meshwork (goniosynechialysis) during surgery to reopen blocked angle segments. This is often combined with cataract extraction or other glaucoma procedures. The purpose is to restore as much natural drainage as possible, though re-closure from the abnormal endothelial membrane can occur.

4. Penetrating keratoplasty (full-thickness corneal transplant)
   When corneal edema becomes severe and vision is markedly reduced, a full-thickness corneal transplant may be considered. The surgeon removes the diseased cornea and replaces it with a donor graft. In ICE syndromes, transplants may be at risk of endothelial failure over time because abnormal cells can recur, so careful follow-up is needed. The purpose is to restore corneal clarity and improve vision.

5. Endothelial keratoplasty (DSEK/DSAEK/DMEK)
   Selective endothelial keratoplasty replaces only the inner layers of the cornea, leaving the outer structure intact. Procedures like DSEK or DMEK offer faster recovery and less induced astigmatism than full-thickness grafts. They are considered when endothelial failure dominates and the rest of the cornea is structurally sound. In ICE-affected eyes, recurrence risk still exists, but these surgeries can significantly improve vision and comfort.

---

Preventions

There is no proven way to prevent Cogan-Reese syndrome itself because the exact cause is unknown. However, the following measures may help prevent or limit complications and vision loss:

1. Early eye examination for any unilateral vision changes, iris color change, or pupil distortion.

2. Regular follow-up with a glaucoma or cornea specialist once diagnosed.

3. Strict adherence to glaucoma medicines and post-surgical instructions.

4. Avoidance of unnecessary or unsupervised steroid eye drops.

5. Prompt treatment of ocular herpes or other eye infections.

6. Wearing protective eyewear during sports or high-risk activities.

7. Controlling blood pressure, diabetes, and cholesterol to support optic-nerve health.

8. Avoiding smoking and second-hand smoke exposure.

9. Seeking urgent care for sudden eye pain, halos, or rapid vision loss.

10. Keeping an updated list of eye medicines and surgeries to share with all healthcare providers.

---

When to See a Doctor

People should see an eye doctor immediately if they notice sudden blurred vision in one eye, severe eye pain, halos around lights, redness with decreased vision, or a rapid drop in visual acuity. These symptoms may indicate an acute pressure spike or corneal decompensation that needs urgent treatment to prevent permanent damage.

Anyone with known Cogan-Reese syndrome or ICE-related glaucoma should attend all scheduled follow-ups even when the eye feels normal. Progressive optic-nerve damage from glaucoma is usually painless and can advance silently. New headaches, nausea, or vomiting with eye pain, or sudden worsening of glare and light sensitivity, also warrant prompt evaluation. If there is any doubt, it is safer to call the eye clinic or emergency services quickly.

---

What to Eat and What to Avoid

Diet cannot cure Cogan-Reese syndrome, but a heart-healthy, eye-friendly eating pattern supports blood vessels and nerves.

1. Eat plenty of colorful vegetables and fruits – provide antioxidants (vitamins C, E, carotenoids) that help protect ocular tissues from oxidative stress.

2. Choose whole grains instead of refined grains – stabilize blood sugar and support vascular health, helpful if diabetes is present.

3. Include fish or plant omega-3 sources several times per week – such as fatty fish, flaxseeds, chia, or walnuts, to support cardiovascular and tear-film health.

4. Use healthy fats (olive oil, nuts, seeds) instead of trans-fats – to reduce inflammation and improve lipid profile.

5. Stay well-hydrated with moderate, steady fluid intake – avoid sudden very large fluid boluses, which may transiently influence IOP in some glaucoma patients.

6. Limit very salty processed foods – to avoid fluid retention and blood-pressure spikes that can stress the cardiovascular system.

7. Limit sugary drinks and excessive sweets – to reduce diabetes and metabolic-syndrome risk, which can harm small ocular vessels.

8. Avoid heavy alcohol intake – excessive alcohol can affect general health and medication adherence; small or no alcohol is safer for most people with chronic eye disease.

9. Avoid excessive caffeine and energy drinks – high doses may transiently raise IOP in some individuals; moderate tea or coffee is usually acceptable but should be discussed with clinicians.

10. Avoid unregulated “miracle eye” supplements – products making unrealistic promises may interact with medicines or pose safety risks; always check with a doctor before starting new supplements.

---

Frequently Asked Questions (FAQs)

1. Is Cogan-Reese syndrome the same as Cogan syndrome?
   No. Cogan-Reese syndrome is an eye-only condition within the ICE syndrome group, while “Cogan syndrome” is a different autoimmune disease involving the eyes and inner ears. The names are similar but they are distinct disorders with different causes and treatments.

2. Is Cogan-Reese syndrome hereditary?
   Current evidence suggests ICE syndromes, including Cogan-Reese, are usually not hereditary and typically affect only one eye. Most patients have no family history of the disease. Close relatives do not usually need special screening beyond routine eye care, although any new eye symptoms should be checked.

3. What symptoms should make me worry about Cogan-Reese syndrome?
   Common signs include a change in iris color or texture, small pigmented nodules on the iris surface, pupil distortion, unilateral blurred vision, halos around lights, or eye discomfort. Because these signs can be subtle at first, any new asymmetrical eye change deserves a professional examination.

4. How is Cogan-Reese syndrome diagnosed?
   Diagnosis is based on slit-lamp examination showing abnormal corneal endothelium, peripheral anterior synechiae, and characteristic iris nodules or pigmented lesions. Gonioscopy, specular microscopy, and sometimes anterior-segment OCT help document endothelial and angle changes. Intraocular pressure and optic-nerve status are also assessed to detect glaucoma.

5. Does everyone with Cogan-Reese syndrome develop glaucoma?
   Most patients develop secondary angle-closure glaucoma at some point because the abnormal membrane progressively blocks the drainage angle. However, the speed and severity of glaucoma vary widely. Some people are controlled for years on medicines; others need early surgery. Regular monitoring is essential to catch pressure rises early.

6. Can Cogan-Reese syndrome cause blindness?
   Yes, if untreated, severe glaucoma and corneal failure can cause major, sometimes irreversible, vision loss. With modern glaucoma medicines, timely surgery, and careful follow-up, many patients maintain useful vision for many years. The key is early detection, consistent treatment, and rapid response to any worsening symptoms.

7. Will I need surgery for Cogan-Reese syndrome?
   Many patients eventually need glaucoma surgery, especially if IOP remains high despite multiple medicines. Some also require corneal transplantation when endothelial failure causes persistent edema and opacity. Your doctor will recommend surgery based on optic-nerve status, corneal clarity, and response to drops and systemic medicines.

8. Can Cogan-Reese syndrome affect both eyes?
   ICE syndromes are classically unilateral, meaning they affect one eye. Rarely, subtle endothelial abnormalities may be seen in the other eye, but clinically significant bilateral disease is uncommon. Nonetheless, ophthalmologists usually check both eyes carefully at each visit to ensure the fellow eye remains healthy.

9. Is there any way to stop the abnormal endothelial cells from growing?
   At present, there is no medicine that reliably stops or reverses the abnormal endothelial membrane in ICE syndromes. Treatment focuses on managing the consequences—glaucoma and corneal edema—rather than the root cause. Research into endothelial cell therapies and other approaches is ongoing, but these options are not yet standard care.

10. Can lifestyle changes alone control Cogan-Reese glaucoma?
    No. Healthy lifestyle habits support overall health and may help the optic nerve cope with stress, but they cannot replace glaucoma medicines or surgery. Cogan-Reese-related glaucoma is typically too aggressive to manage with lifestyle changes alone. Eye-drop adherence and timely surgery are the foundation of treatment.

11. Are there special precautions for surgery in Cogan-Reese eyes?
    Yes. Surgeons must consider the risk of abnormal membrane proliferation, synechiae formation, and endothelial fragility. They may select particular glaucoma implants, use anti-fibrotic agents, and carefully manage inflammation. Post-operative follow-up is usually close, and adjustments to medicines are common to keep IOP stable and protect the cornea.

12. Can I still use a computer or smartphone with Cogan-Reese syndrome?
    In most cases, yes. Using screens does not worsen the underlying disease, but glare and visual fatigue may be more pronounced if corneal edema or visual-field loss is present. Adjusting brightness, using larger fonts, taking regular breaks, and ensuring good ambient lighting can make screen use more comfortable.

13. What about driving with Cogan-Reese syndrome?
    Driving safety depends on visual acuity and visual field in both eyes and must follow local legal standards. Some patients with well-controlled disease and good vision can drive safely; others with advanced glaucoma or corneal opacity may not meet legal requirements. The eye doctor can advise based on formal vision and field tests.

14. Can children develop Cogan-Reese syndrome?
    Cogan-Reese syndrome is typically described in young-to-middle-aged adults, and pediatric cases are very rare. If a child shows unusual iris changes or unexplained unilateral glaucoma, specialists will consider a broad list of diagnoses, including anterior-segment dysgenesis, trauma, and other conditions, and may evaluate for ICE-like features when appropriate.

15. What is the long-term outlook?
    The long-term prognosis varies. Some patients retain good vision for decades with careful monitoring, while others experience progressive optic-nerve damage or corneal failure despite treatment. The outlook is better when the disease is diagnosed early, IOP is kept low, and surgeries are performed before severe, irreversible optic-nerve or corneal damage occurs. Lifelong follow-up with an experienced ophthalmologist is essential.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: February 03, 2025.